ReShape Lifesciences amends convertible note, extends maturity to April 2025

Vyome Holdings, Inc

Maturity extended to earlier of Vyome Therapeutics merger close or 90 days after Jan 14, 2025 (April 16, 2025).
Mandatory prepayment of subsequent financing proceeds reduced from 66% to 50%.
Investor not required to convert the note at merger closing; $45,000 cash extension fee payable at maturity.
Amendment executed with Ascent Partners Fund LLC on $833,333.34 senior secured convertible note.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.